October 9, 2021

Oyster Point Pharma, Inc. (OYST) increased by 5.79% in the aftermarket. However, the last trading session closed at $11.05 with an incline of 0.36%. OYST Reports Inducement Grants Under Nasdaq Listing Rule On 1st September 2021, OYST announced that the company’s Board of Directors issued inducement non-qualified stock options to 110 new employees to acquire […]

Build-A-Bear Workshop, Inc. (BBW) rose by 5.04% in the aftermarket. However, the last trading session concluded at $16.46 with a decrease of 2.83%. BBW Celebrates Back to School Season On 7th September 2021, Build-A-Bear announced that it has added some magical new items to its Harry Potter-themed collection. Guests may wear new clothes and accessories

America First Multifamily Investors, L.P. (ATAX) saw a push of 5.25% in the aftermarket. However, the last trading session closed at $6.09 with a decline of 1.14%. Closing of Public Offering of Beneficial Unit Certificates On 28th September 2021, ATAX stated that it has completed its previously announced underwritten public offering of 4,750,000 beneficial unit

Urban-gro, Inc. (UGRO) experiences an incline of 5.52% in the aftermarket. However, the last trading session concluded at $12.87 with a decrease of 3.88%. XS Financial Enters into Strategic Partnership with UGRO On 5th October 2021, URGO and XS have formed a strategic collaboration. This agreement allows XS Financial to provide CAPEX leasing options to

The Glimpse Group, Inc. (VRAR) has seen a sudden increase of 5.34% in the aftermarket. However, the last trading session closed at $7.31 with an incline of 0.83%. QReal Hires Leading Instagram Enterprise Augmented Reality Experience Designer, Ege Islekel, as Creative Manager On 5th October 2021, VRAR stated that the company has hired Ege Islekel

Achieve Life Sciences, Inc. (ACHV) has seen an incline of 6.56% in the aftermarket. However, the last trading session closed at $8.39 with an increase of 1.08%. Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards On 13th August 2021, ACHV announced the employment of a Director of Clinical Operations, a Senior Manager

Lava Therapeutics B.V. (LVTX) has experienced a decline of 13.92% in the aftermarket. However, the last trading session concluded at $7.11 with an incline of 16.94%. LVTX to Present its Bispecific Gamma Delta T Cell Engagers On 7th October 2021, LVTX announced that the chief scientific officer, Hans van der Vliet, will speak at the